Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4<sub>p230-239</sub>/HLA-A∗02:01 complex.

导出 OA

翻译打印收藏纠错

作者： Linan,Wang ^[1] ; Masahiro,Matsumoto ^[2] ; Yasushi,Akahori ^[3] ; Naohiro,Seo ^[1] ; Kazuko,Shirakura ^[1] ; Takuma,Kato ^[4] ; Yoichi,Katsumoto ^[2] ; Yoshihiro,Miyahara ^[5] ; Hiroshi,Shiku ^[6]

作者单位： Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan. ^[1] Tokyo Laboratory 11, R&D Center, Sony Group Corporation, Bunkyo-ku, Tokyo 113-8510, Japan. ^[2] Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan; Center for Comprehensive Cancer Immunotherapy, Mie University, Tsu, Mie 514-8507, Japan. ^[3] Department of Cellular and Molecular Immunology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan. ^[4] Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan; Center for Comprehensive Cancer Immunotherapy, Mie University, Tsu, Mie 514-8507, Japan. Electronic address: miyahr-y@med.mie-u.ac.jp. ^[5] Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan; Center for Comprehensive Cancer Immunotherapy, Mie University, Tsu, Mie 514-8507, Japan. Electronic address: shiku@med.mie-u.ac.jp. ^[6]

关键词 CAR GITR ICD MAGE-A4 peptide MHC complex pMHC